Q-omics provides the consensus-scored TRIM64DP profile across patient tissues and cancer cell-line models. TRIM64DP expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRIM64DP is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, TRIM64DP RNA expression shows 5,483 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, LUSC, and STAD as cancer lineages where TRIM64DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM64DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM64DP survival associations across molecular data types. TRIM64DP RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM64DP RNA expression–survival associations across cancer types. High TRIM64DP expression shows unfavorable associations in UCEC, BLCA, PAAD, LGG, GBM and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify UCEC as the clearest survival context for TRIM64DP RNA expression.
This table summarizes TRIM64DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM64DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM64DP shows higher tumor expression in LUSC. The LUSC box plot shows higher TRIM64DP RNA expression in tumor versus normal tissue (log2 FC = +0.005, t-test p = .033).
This table shows molecular features associated with TRIM64DP in patient tissues and cancer cell lines. In patient samples, TRIM64DP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
